Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Record History

See every version on ClinicalTrials.gov ↗

1. Minor Changed Oct 4, 2026 Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
2. Notable Sep 17, 2024 Start date: Aug 1, 2024 to Oct 1, 2024v4
3. Notable Jul 31, 2024 Primary completion date: Oct 30, 2024 to Oct 31, 2025v3 Show 5 more changesShow less

   • Study completion date: Apr 30, 2027 to Apr 30, 2026
   • Eligibility criteria expanded, about 32 words
   • Secondary endpoints: details revised at 3 of 4 entries
   • Study description shortened, about 18 words
   • Study title shortened, about 8 words
4. Notable Jul 18, 2024 Enrollment target: 20 to 80v2 Show 5 more changesShow less

   • Primary endpoint revised
   • Secondary endpoints: 2 to 4
   • Study description expanded, about 18 words
   • Study arms: 1 to 2
   • Study title expanded, about 4 words
5. Minor Jul 5, 2024 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.